Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Statement

12 Apr 2018 07:00

RNS Number : 6330K
Scapa Group PLC
12 April 2018
 

 

12 April 2018

 

Scapa Group plc ("Scapa" or "the Group")

 

Year-end trading update

 

Scapa Group plc (AIM: SCPA) is today providing an unaudited year end update for the twelve months ended 31 March 2018.  

 

The Group performed well and the good progress reported in the Interim Results has continued. Overall Group results are in line with the improved expectations outlined in the Group's October trading update.

Healthcare: Revenues grew 3.8% for the year, despite currency headwinds in H2. Sales growth in H2 was strong at 6.8% on a constant currency basis. Margins for the year are expected to be above 15% reflecting the investment in the integration of two technology transfers completed during the year.

Industrial: Industrial continues to deliver on its asset optimisation strategy. Industrial margin further improved driven by the benefit of Asian restructuring and more efficient cost to serve. The Markel acquisition is complete and site consolidations are underway.

Healthy cash flow in the period ensured the Group ended the year with net debt of ÂŁ3.8m, after the acquisition of Markel Industries for US$10.2m (ÂŁ7.6m) and BioMed Laboratories LLC for US$19m (ÂŁ13.6m).

Heejae Chae, CEO commented:

"This year we have delivered another set of strong results, and completed two acquisitions: Markel, our first Industrial acquisition, and BioMed, our first Healthcare acquisition outside adhesive technology. We also completed two technology transfers in Healthcare as we execute our growth strategy. I believe there is clear potential, in both Healthcare and Industrial, to further improve performance through organic growth, efficiency and acquisitions.

It is with great sadness that we announced yesterday a fatal accident at the Dunstable facility in the UK. I join with all of my colleagues and fellow directors in expressing our sincere condolences to the family and friends of the deceased."

Scapa expects to report its full year results on 22 May 2018.

This announcement contains inside information.

For further information:

Scapa Group plc Heejae Chae - Chief Executive Tel: 0161 301 7430

Graham Hardcastle - Finance Director

 

Numis Securities Limited Mark Lander, Richard Thomas Tel: 020 7260 1000

(Nominated Adviser/Joint Broker)

 

Berenberg Chris Bowman Tel: 020 3207 7800

(Joint Broker)

 

Weber Shandwick Financial PR Nick Oborne Tel: 0207 067 0000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKDDPPBKDBQD
Date   Source Headline
1st Dec 201510:11 amRNSHolding(s) in Company
1st Dec 201510:10 amRNSHolding(s) in Company
30th Nov 201510:34 amRNSTotal Voting Rights
24th Nov 20157:00 amRNSInterim Results
3rd Nov 20154:55 pmRNSHolding(s) in Company
3rd Nov 20154:54 pmRNSShareholder Circular Posted
13th Oct 20157:00 amRNSTrading Statement
10th Sep 20151:03 pmRNSAdditional Listing
9th Sep 20159:48 amRNSHolding(s) in Company
1st Sep 20153:57 pmRNSBlocklisting Interim Review
1st Sep 20153:29 pmRNSAdditional Listing
11th Aug 20151:28 pmRNSAdditional Listing
10th Aug 20159:46 amRNSDirector/PDMR Shareholding
23rd Jul 20159:21 amRNSDirector/PDMR Shareholding
21st Jul 20157:00 amRNSAGM Statement
14th Jul 20153:56 pmRNSAdditional Listing
13th Jul 20151:26 pmRNSHolding(s) in Company
2nd Jul 201511:15 amRNSAdditional Listing
17th Jun 20157:00 amRNSHealthcare Site Visit
16th Jun 20159:15 amRNSAdditional Listing
10th Jun 20152:54 pmRNSHolding(s) in Company
5th Jun 20159:01 amRNSHolding(s) in Company
4th Jun 20159:31 amRNSHolding(s) in Company
3rd Jun 20158:59 amRNSHolding(s) in Company
27th May 20157:00 amRNSFinal Results
28th Apr 20153:27 pmRNSAdditional Listing
9th Apr 20157:00 amRNSTrading Statement
7th Apr 20154:38 pmRNSHolding(s) in Company
7th Apr 20153:43 pmRNSAdditional Listing
31st Mar 20159:12 amRNSTotal Voting Rights
30th Mar 20154:02 pmRNSAdditional Listing
30th Mar 20152:58 pmRNSDirector/PDMR Shareholding
18th Mar 20154:45 pmRNSHolding(s) in Company
16th Mar 20154:20 pmRNSAdditional Listing
10th Mar 20154:10 pmRNSAdditional Listing
9th Mar 20157:00 amRNSHolding(s) in Company
5th Mar 20157:00 amRNSDirector/PDMR Shareholding
5th Mar 20157:00 amRNSDirector/PDMR Shareholding
4th Mar 20157:00 amRNSDirector/PDMR Shareholding
2nd Mar 20153:58 pmRNSAdditional Listing
2nd Mar 20157:00 amRNSAcquisition
23rd Feb 20159:08 amRNSHolding(s) in Company
16th Feb 20159:01 amRNSHolding(s) in Company
13th Feb 20159:09 amRNSHolding(s) in Company
11th Feb 201510:52 amRNSHolding(s) in Company
9th Feb 20151:35 pmRNSHolding(s) in Company
9th Feb 201510:33 amRNSBlocklisting Interim Review
4th Feb 201512:18 pmRNSHolding(s) in Company
23rd Jan 20159:59 amRNSHolding(s) in Company
31st Dec 201412:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.